SEARCH RESULT

Total Matching Records found : 86

Drugs, Ranbaxy and lies

-The Hindu Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed...

More »

A deception most foul-Narayan Lakshman

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...

More »

Ranbaxy's dark chapter-Bhupesh Bhandari

-The Business Standard Why have Indian authorities woken up to the Ranbaxy case only now? The matter had been simmering for several years The Ranbaxy affair is one of the darkest chapters of India's business history. The company has admitted it fudged data so that it could launch its products in the United States. It has now paid $500 million as a penalty to settle the case. It is worse than Ramalinga...

More »

RTI brings to light drug trial on humans -Syed Intishab Ali

-The Times of India JAIPUR: A doctor conducted drug trial on heart patients but seven of them died during trial of the drug. Moreover, another doctor conducted drug trials of different companies and 10 of his cancer patients died during the trials. An RTI filed by a government-run Indore hospital Dr Anand Rai exposed deaths leading to drug trials in entire country. Answering to the RTI, office ofdrug controller general, ministry of...

More »

Calling big pharma’s bluff -Dwijen Rangnekar

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close